Amelioration of experimental amnesia (passive avoidance failure) in rodents by the selective M1 agonist AF102B.
Effect of AF102B (cis-2-methylspiro-(1,3-oxathiolane-5,3')-quinuclidine) on experimental amnesia was examined using a passive avoidance task in rodents. The amnesia was produced by anti-cholinergic agents, AF64A (intracerebroventricularly) and scopolamine (subcutaneously). AF102B ameliorated the memory deficits in AF64A-treated rats at 0.1-1 mg/kg, i.p. and at 1-5 mg/kg p.o. and in scopolamine-treated mice at 1-10 mg/kg, i.p. These results suggest that AF102B may compensate for central cholinergic defects and could be developed as a possible therapeutic drug for senile dementia of the Alzheimer type.
Nakahara
N
N
Research Institute of Life Science, Snow Brand Milk Products Co., Ltd., Tochigi, Japan.
Iga
Y
Y
Mizobe
F
F
Kawanishi
G
G
D000647:Amnesia / Q000139:chemically induced / Q000503:physiopathology*; D000818:Animals; D001115:Arecoline / Q000494:pharmacology; D001388:Aziridines / Q000633:toxicity; D002794:Choline / Q000031:analogs & derivatives / Q000633:toxicity; D008297:Male; D008568:Memory / Q000187:drug effects*; D051379:Mice; D008815:Mice, Inbred Strains; D010095:Oxotremorine / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology*; D011812:Quinuclidines / Q000494:pharmacology*; D012153:Retention, Psychology / Q000187:drug effects*; D012601:Scopolamine / Q000633:toxicity; D013876:Thiophenes
D001388:Aziridines; D010277:Parasympathomimetics; D011812:Quinuclidines; D013876:Thiophenes; D001115:Arecoline; D010095:Oxotremorine; C044894:ethylcholine aziridinium; D012601:Scopolamine; C059240:cevimeline; D002794:Choline